EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Prevalence of Drug-Related Transaminitis in Post-Renal Transplant Recipients: A Single-Center Study in Peshawar

Farman ullah, Irfan Mirza, Muhammad Izhar, Muhammad Younas Khan

Journal of Gandhara Medical and Dental Science · 01.04.2026 · 13 (2) · 71-76

DOI: 10.37762/jgmds.13-2.789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gandhara Medical and Dental Science, online erschienen am 01.04.2026. Verfasst von Farman ullah und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES This study aimed to estimate the prevalence, timing, pattern, and predictors of drug-related transaminitis among kidney-transplant recipients at a tertiary center in Khyber Pakhtunkhwa, Pakistan. METHODOLOGY The study was conducted at a tertiary care academic hospital in Peshawar, Pakistan, enrolling consecutive adult kidney transplant recipients who attended the transplant service between February 2022 and August 2025 (N=99). The Primary outcome was drug-related transaminitis defined by standard DILI thresholds (ALT/AST ≥3× ULN or ALP ≥2× ULN) with RUCAM causality assessment and CTCAE severity grading. Prespecified predictors included high tacrolimus trough (>10 ng/mL after day 7), azole co-administration, CMV viremia, HCV serostatus, obesity, and age/sex. RESULTSPrevalence of drug-related transaminitis was 26.3% (26/99; 95% CI 18.6-35.7). Median time to onset was 27 days post-transplant and 16 days from culprit-drug exposure. The injury pattern was predominantly hepatocellular (73.1%); 46.2% mild, 30.8% moderate, and 23.1% severe, according to CTCAE. On multivariable analysis, high tacrolimus trough (aOR 3.9; p=0.009), azole co-administration (aOR 2.7; p=0.047), and CMV viremia (aOR 3.1; p=0.035) were independently associated with events. Most cases resolved with dose modification or withdrawal (84.6%) in a median of 21 days; 11.5% required hospitalization; no graft loss or death was attributed to hepatotoxicity. CONCLUSION Approximately one in four post-renal transplant recipients developed drug-related transaminitis, with the strongest signals from supratherapeutic tacrolimus exposure, azole interactions, and CMV viremia. Routine therapeutic-drug monitoring, vigilant interaction checks, and targeted viral surveillance can mitigate risk and expedite recovery.

Zitieren

APA

ullah, F., Mirza, I., Izhar, M., & Khan, M. Y. (2026). Prevalence of Drug-Related Transaminitis in Post-Renal Transplant Recipients: A Single-Center Study in Peshawar. Journal of Gandhara Medical and Dental Science, 13(2), 71-76. https://doi.org/10.37762/jgmds.13-2.789

Vancouver

ullah F, Mirza I, Izhar M, Khan MY. Prevalence of Drug-Related Transaminitis in Post-Renal Transplant Recipients: A Single-Center Study in Peshawar. Journal of Gandhara Medical and Dental Science. 2026;13(2):71-76. doi:10.37762/jgmds.13-2.789

BibTeX
@article{ullah2026,
  author = {ullah, Farman and Mirza, Irfan and Izhar, Muhammad and Khan, Muhammad Younas},
  title = {Prevalence of Drug-Related Transaminitis in Post-Renal Transplant Recipients: A Single-Center Study in Peshawar},
  journal = {Journal of Gandhara Medical and Dental Science},
  year = {2026},
  volume = {13},
  number = {2},
  pages = {71--76},
  doi = {10.37762/jgmds.13-2.789}
}
Kostenlos starten →